Amlal Pharmaceuticals

Amlal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel topical therapies for inflammatory and autoimmune skin diseases. The company's primary focus is on its lead candidate, AML-101, a potent and selective topical Janus kinase (JAK) inhibitor. AML-101 is currently being evaluated for the treatment of alopecia areata, vitiligo, and psoriasis, aiming to provide a safer alternative to systemic treatments. By utilizing a topical delivery system, Amlal seeks to maximize local efficacy while minimizing systemic exposure and associated side effects. Headquartered in Farmington, Connecticut, the company was founded as a spin-out from the University of Connecticut. Amlal is led by an experienced management team with a track record in dermatology drug development and commercialization.